Medtronic, Inc.

Warsaw Orthopedic, Inc.

Cerebral Therapeutics, Inc.

Lisa Lynn Shafer

Deepak Ramesh Thakker

James R Keogh

Matthew David Bonner

Michael R S Hill

Francis J Carr

Tim Jones

Steve R LaPorte

James Peter Gregson

Dawn Ann Bembridge

John Myers Zanella

Michael Eric Benz

Eric Burright

Daniel J Abrams

Greg Stewart

Bill McKay

Peter T Schroeder

Eric N Burright

Jennifer M Christianson

Rodolfo Padua

An implantable medical device for delivering therapeutic fluid to, and withdrawing cerebrospinal fluid (CSF) from, a CSF-containing space, includes a first inlet configured to be accessed by a needle of an aspiration device; a first outlet; a first fluid pathway extending from the first inlet to the first outlet; a second inlet; a second outlet; and a second fluid pathway extending from the second inlet to the second outlet. The first fluid pathway is free of a filter configured to prevent passage of a microbe.

Medical device having non-filtered CSF withdrawal pathway

Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Methods for distributing agents to areas of brain

Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (A&#x3b2;), and the methods, agents and devices are useful for reducing the accumulation of A&#x3b2;, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A&#x3b2;, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to A&#x3b2;, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Methods and device to neutralize soluble toxic agents in the brain

Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include A&#x3b2;, and the methods, agents and devices are useful for reducing the accumulation of A&#x3b2;, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to A&#x3b2;, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to A&#x3b2;, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF&#x3ba;B family of transcription factors.

Systems and methods to treat pain locally

Devices and methods for treating diseases associated with loss of neuronal function are described. The methods are designed to promote proliferation, differentiation, migration, or integration of endogenous progenitor stem cells of the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region containing endogenous stem cells or a CNS region where the endogenous stem cells are predicted to migrate and eventually reside, or a combination thereof.

Method for treating damaged tissue of the CNS

Humanized anti-A&#x3b2; antibodies derived from a murine antibody directed to a N-terminal epitope of A&#x3b2; are described. The humanized antibodies have reduced or no human T cell epitopes and bind A&#x3b2; with an affinity similar to that of the murine antibody.

Humanized anti-amyloid beta antibodies

Antibody complexes including anti-A&#x3b2; antibodies conjugated with a sialic acid-containing molecule show improved bioavailability with no significant adverse effects on binding to amyloid beta.

Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules

Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis

Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, is provided to attenuate an immune response, including an inflammatory immune response. Devices such as pulse generators and drug pumps may be used to stimulate the sympathetic nervous system to attenuate an immune response. Systems optionally having one or more sensors and operator instructions may also be used. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.

Device and method for inhibiting release of pro-inflammatory mediator

A method of performing a medical procedure is provided. The medical procedure includes stimulation of a patient's heart while stimulating a nerve of the patient in order to modulate the patient's inflammatory process. More particularly, the medical procedure includes pacing the ventricles of the patient's heart while stimulating the vagal nerve of the patient. Systems and devices for performing the medical procedure are also provided.

Method and system for vagal nerve stimulation with multi-site cardiac pacing

Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.

Growing community of inventors

Stillwater, MN, United States of America

Lisa Lynn Shafer